Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.

Cancer research - 1 Mar 2004

Sharkey Melinda S, Lizée Gregory, Gonzales Monica I, Patel Sima, Topalian Suzanne L

Abstract excerpt

The potential of antigen-directed cancer immunotherapy has not been fully realized, perhaps because many commonly targeted tumor associated proteins are not essential to maintaining the malignant cell phenotype. A constitutively activating mutation in the signaling molecule BRAF is expressed freq...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to HLA-DP Antigens
Share to HLA-DP beta-Chains

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DQ Antigens

Share to HLA-DQ beta-Chains

Share to HLA-DR Antigens

Share to HLA-DRB1 Chains

Share to Proto-Oncogene Proteins c-raf

Source

Identifiers

PMID: 14996715
DOI: 10.1158/0008-5472.can-03-3231

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-14996715-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.PMID 14996715Read ↗

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.Semantic proximity Read ↗

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.Semantic proximity Read ↗

Immunogenicity of constitutively active V599EBRaf.Semantic proximity Read ↗

V599EB-RAF is an Oncogene in MelanocytesSemantic proximity Read ↗

Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptorsSemantic proximity Read ↗

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.Semantic proximity Read ↗

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.Semantic proximity Read ↗

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.Semantic proximity Read ↗

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.Semantic proximity Read ↗

Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.Semantic proximity Read ↗

A ras- Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma LesionSemantic proximity Read ↗

Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.